Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes

被引:22
作者
Houghton, Colin S. B.
Engelhorn, Manuel E.
Liu, Cailan
Song, Da
Gregor, Polly
Livingston, Phillip O.
Orlandi, Francesca
Wolchok, Jedd D.
McCracken, James
Houghton, Alan N.
Guevara-Patino, Jose A.
机构
[1] Mem Sloan Kettering Canc Ctr, Swim Across Amer Lab, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Res Comp Dept, New York, NY 10021 USA
[3] Univ Chicago, Lab Tumor Immunol & Canc Vaccine Dev, Chicago, IL 60637 USA
关键词
T cells; antigens/peptides/epitopes; tumor immunity; vaccination; CYTOTOXIC T-LYMPHOCYTES; PEPTIDE BINDING; MELANOMA PATIENTS; ANCHOR RESIDUES; METASTATIC MELANOMA; ANTIGENIC PEPTIDES; TUMOR-IMMUNITY; CELL RESPONSE; ELISPOT ASSAY; CTL EPITOPES;
D O I
10.1016/j.vaccine.2007.05.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
One strategy to generate T-cell responses to tumors is to alter subdominant epitopes through substitution of amino acids that are optimal anchors for specific MHC molecules, termed heteroclitic epitopes. This approach is manually error-prone and time-consuming. In here, we describe a computer-based algorithm (EpitOptimizer) for the streamlined design of heteroclitic epitopes. Analysis of two cancer-related proteins showed that EpitOptimizer-generated peptides have enhanced MHC-I binding compared with their wild-type counterparts; and were able to induce stronger CD8+ T-cell responses against their native epitope. These data demonstrate that this approach can serve as the basis of epitope-engineering against cancer and intracellular pathogens. Published by Elsevier Ltd.
引用
收藏
页码:5330 / 5342
页数:13
相关论文
共 48 条
[1]   Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer [J].
Alexander, RB ;
Brady, F ;
Leffell, MS ;
Tsai, V ;
Celis, E .
UROLOGY, 1998, 51 (01) :150-157
[2]   Sequence signals for generation of antigenic peptides by the proteasome: Implications for proteasomal cleavage mechanism [J].
Altuvia, Y ;
Margalit, H .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 295 (04) :879-890
[3]  
Bakker ABH, 1997, INT J CANCER, V70, P302, DOI 10.1002/(SICI)1097-0215(19970127)70:3<302::AID-IJC10>3.0.CO
[4]  
2-H
[5]   The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays [J].
Britten, CM ;
Meyer, RG ;
Kreer, TA ;
Drexler, I ;
Wölfel, T ;
Herr, W .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 259 (1-2) :95-110
[6]   INDUCTION OF ANTITUMOR CYTOTOXIC T-LYMPHOCYTES IN NORMAL HUMANS USING PRIMARY CULTURES AND SYNTHETIC PEPTIDE EPITOPES [J].
CELIS, E ;
TSAI, V ;
CRIMI, C ;
DEMARS, R ;
WENTWORTH, PA ;
CHESNUT, RW ;
GREY, HM ;
SETTE, A ;
SERRA, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2105-2109
[7]  
Cormier JN, 1997, CANCER J, V3, P37
[8]   ENDOGENOUS PEPTIDES BOUND TO HLA-A3 POSSESS A SPECIFIC COMBINATION OF ANCHOR RESIDUES THAT PERMIT IDENTIFICATION OF POTENTIAL ANTIGENIC PEPTIDES [J].
DIBRINO, M ;
PARKER, KC ;
SHILOACH, J ;
KNIERMAN, M ;
LUKSZO, J ;
TURNER, RV ;
BIDDISON, WE ;
COLIGAN, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (04) :1508-1512
[9]   Heteroclitic immunization induces tumor immunity [J].
Dyall, R ;
Bowne, WB ;
Weber, LW ;
LeMaoult, J ;
Szabo, P ;
Moroi, Y ;
Piskun, G ;
Lewis, JJ ;
Houghton, AN ;
Nikolic-Zugic, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1553-1561
[10]  
ENGLAND RD, 1995, J IMMUNOL, V155, P4295